Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 11/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304336 | 0.95 | CYP1A1 (0.45) | F2CYP1A1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12354086 | 0.91 | CYP1A1 (0.43) | F2CYP1A1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14217380 | 0.88 | CYP1A1 (0.42) | F2CYP1A1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14217369 | 0.87 | CYP1A1 (0.53) | F2CYP1A1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14708686 | 0.87 | CYP1A1 (0.46) | F2CYP1A1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12353905 | 0.84 | ALDH1A1 (0.51) | CYP1A1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14217340 | 0.84 | F2 (0.44) | F2CYP1A1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2304867 | 0.84 | CYP1A1 (0.44) | CYP1A1LMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2303056 | 0.84 | LMNA (0.56) | CYP1A1LMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2235106 | 0.84 | LMNA (0.56) | CYP1A1LMNASMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | F2 3607/4885CYP1A1 1777/4885LMNA 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.